🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NIAGRA: neoadjuvant gem/cis +/- perioperative durvalumab shows significant OS and EFS. #GU25 Matt Galsky now shows the prognostic relevance of pCR. It also showed the durvalumab outperforms the control arm irrespective of pCR. OncoAlert

I love being provocative and I love to see people provocative at the stage. For me, it makes us to come out the comfort zone and think beyond. What a lovely conclusion from Elizabeth Plimack MD in her terrific discussion of perioperative treatment of MIBC at ASCO #GU25. It merits to

Best Q&A session ever in #GU25. Matt Galsky Tom Powles Elizabeth Plimack MD Cora Sternberg arguing over best treatment approach in localized Bladder cancer upon presentation of NIAGARA and CM274 updated results!! Excellent discussion from Elizabeth Plimack MD. Petros Grivas OncoAlert

ASCO GU 2025: KEYMAKER-U03B 💊 Lenvatinib + Belzutifan shows durable activity in pretreated aRCC 🔬 Supports further investigation in LITESPARK-011 Katy Beckermann Laurence Albiges Toni Choueiri, MD ASCO Yüksel Ürün #GU25 Emre Yekedüz

A great talk by Tian Zhang, MD, MHS in terms of current and future approaches in RCC! ASCO #GU25 OncoAlert Yüksel Ürün Toni Choueiri, MD Nazli Dizman OncLive.com Dana-Farber Lank Center for Genitourinary Oncology Sumanta K. Pal, MD, FASCO Bárbara Melão, MD, PhD Dra. María Natalia Gandur Quiroga

Our very own Wenxin (Vincent) Xu taking the stage to discuss his outstanding work on KIM-1 as a biomarker of response to immunotherapy in #RCC High baseline KIM-1 = Worse outcomes Early KIM-1 drop on NIVO+IPI = Major survival benefit 3-week >30% decrease ➡️ ORR 69%, mPFS 71 mo, mOS

Trending 10 key trials among oncologists on X following ASCO-GU 2025, spotlighted by LARVOL CLIN. #LARVOL #GU25 #Oncology #CancerResearch #CancerData #GUCancer #GenitourinaryOncology #ClinicalTrials

Congrats Valérie Fonteyne Flor Verghote 👌Nice job and a new step in the Adjuvant RT field for MIBC patients, SAFE and EFFICIENT! Vedang Murthy John Christodouleas sciencedirect.com/science/articl…

Amazing talks and plenty to take back to the clinic. Come back soon Timothée Olivier, MD

Guiding Treatment for Patients With Prostate Cancer With Biochemical Recurrence After Prostatectomy dailynews.ascopubs.org/do/guiding-tre… with Amar Kishan Daniel E Spratt Thanks ASCO Daily News Related Nature Reviews Urology article: pubmed.ncbi.nlm.nih.gov/34363040/ x.com/NicholasZaorsk…

Congrats Zayd!

NIAGARA’s surgical safety results #EAU25 with Jim Catto. Results show the addition of duvalumab to neoadjuvant platinum chemotherapy did not increase surgical complications or cystectomy rates.

Great to see this guy at Leeds when discussing 👍#kidneycancer. Unfortunately I was a definite last place in the Enrique Grande lookalike competition that Naveen Vasudev won last year !!!

Syed A Hussain this is of course for those patients who choose to undergo RC not those who choose bladder preservation with chemo rad. & not a reason 2b steered down surgical option pathway Prof Ananya💙 @achoud72.bsky.social Nick James also on @Prof-Nick-James.bsky.social jim catto Robert Huddart💙 World Bladder Cancer Patient Coalition Fight Bladder Cancer

🚀 New study published in #EJC! This 🇪🇺 retrospective study evaluated the activity of #lenvatinib in 133 previously treated patients with metastatic #RCC #kidneycancer. 🔗sciencedirect.com/science/articl… OncoDaily UroToday.com GU Oncology Now OncoAlert

📄 New analysis from the TITAN trial: 🔍 In mCSPC patients treated with apalutamide: • 🧬 Discordant progression occurred in 52.2% of patients (60 of 115) in the apalutamide group and 27.5% (58 of 211) in the placebo group (p < 0.001) 📢 Takeaway: PSA alone isn’t enough—routine

Day 1 ESMO - Eur. Oncology #Preceptorship in Metastatic #urothelial #RCC #cancer 62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC ESMO - Eur. Oncology #guidelines

sacituzumab govitecan (SG) vs sacituzumab tirumotecan (Sac-TMT) = antibody ≈ DAR (7.6 vs 7.4) ≠ conjugation chemistry (maleimide vs pyrimidine) ≈ linker (except conjugation part) = carbonate cleavable group ≠ payload structure and properties (SN-38 vs KL610023)

Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic #UrothelialCarcinoma: a single-center retrospective study from 2004 to 2021. Author commentary on UroToday > bit.ly/40Lmbye Jose C. Tapia

All patients who received a personalized #vaccine for advanced #kidneycancer achieved an immune response, according to results of a phase 1 trial. Healio spoke with David Braun of Yale School of Medicine and Yale Cancer Center about the data and its implications. 🔗Read here bit.ly/3QJDSd6